Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804922 | 0.98 | KDM4E (0.59) | KDM4EPOLBSMN1; SMN2MAPTGAA | |
| SCHEMBL2633979 | 0.98 | KDM4E (0.59) | KDM4EPOLBSMN1; SMN2MAPTGAA | |
| Hydrochloric Acid SCHEMBL27566194 | 0.96 | KDM4E (0.57) | KDM4EPOLBSMN1; SMN2MAPTGAA | |
| SCHEMBL9239536 | 0.80 | KDM4E (0.63) | KDM4EPOLBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL17509 | 0.78 | SMN1; SMN2 (0.56) | POLBSMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL29483829 | 0.78 | SMN1; SMN2 (0.56) | POLBSMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL770389 | 0.78 | MEN1 (0.48) | POLBSMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL8438731 | 0.78 | KDM4E (0.65) | KDM4EPOLBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4804914 | 0.77 | SMN1; SMN2 (0.59) | POLBSMN1; SMN2MAPTGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL4803286 | 0.77 | SMN1; SMN2 (0.55) | POLBSMN1; SMN2MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | KDM4E 1938/4885POLB 4481/4885SMN1; SMN2 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.